var data={"title":"Aztreonam (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aztreonam (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/783820?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aztreonam-systemic-drug-information\" class=\"drug drug_general\">see &quot;Aztreonam (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=aztreonam-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aztreonam (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768890\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Azactam;</li>\n      <li>Azactam in Dextrose</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29837372\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30027754\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection:</b> IM, IV (<i>Red Book</i> [AAP 2015]): <b>Note: </b>Higher doses (ie, 50 mg/kg/dose) may be required when treating <i>Pseudomonas</i> infections</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Body Weight</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Postnatal Age</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Dose</b></p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;14 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 8 to 12 hours</p></td></tr>\n        <tr>\n          <td rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;2 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;7 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 8 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 28 days</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg/dose every 6 hours</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29837376\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=aztreonam-systemic-drug-information\" class=\"drug drug_general\">see &quot;Aztreonam (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents (<i>Red Book</i> [AAP 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infection: IM, IV: 90 mg/kg/day in divided doses every 8 hours; maximum daily dose: 3,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infection: IM, IV: 90 to 120 mg/kg/day in divided doses every 6 to 8 hours; maximum daily dose: 8 g/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis </b>\n      <i>\n        <b>(Pseudomonas aeruginosa)</b></i>\n      <b>:</b> Infants, Children, and Adolescents: IV: 150 to 200 mg/kg/day in divided doses every 6 to 8 hours (Kliegman 2016); higher doses have been used: 200 to 300 mg/kg/day divided every 6 hours; maximum daily dose: 12 <b>g</b>/day (Zobell 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections, complicated:</b> Infants, Children, and Adolescents: IV: 90 to 120 mg/kg/day divided every 6 to 8 hours in combination with metronidazole; maximum dose: 2,000 mg (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis), treatment:</b> Infants, Children, and Adolescents: Intraperitoneal: Continuous: Loading dose: 1,000 mg per liter of dialysate; maintenance dose: 250 mg per liter (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis, treatment: </b>Children and Adolescents: IV: 30 mg/kg within 60 minutes before procedure; may repeat in 4 hours for prolonged procedure or excessive blood loss; maximum dose: 2,000 mg (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection: </b>\n      <b>Note:</b> Higher doses (8 to 12 <b>g</b> daily) may be needed for patients with cystic fibrosis (Zobell 2013) or other infections (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderately severe systemic infections:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 1,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 1,000 to 2,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe systemic or life-threatening infections (especially if caused by <i>Pseudomonas aeruginosa</i>): IV: 2,000 mg every 6 to 8 hours; maximum daily dose: 8 <b>g/day </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection:</b> IM, IV: 500 to 1,000 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: IM, IV: The following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 90 to 120 mg/kg/day divided every 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10-29 mL/minute/1.73 m<sup>2</sup>: 15 to 20 mg/kg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 7.5 to 10 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 7.5 to 10 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 7.5 to 10 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 30 mL/minute: Give 50% of the usual dose at the usual interval</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Give a full first dose, then give 25% of the dose at the usual interval</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Dialyzable (20% to 50%); loading dose of 500 mg, 1,000 mg, or 2,000 mg, followed by 25% of initial dose at usual interval; for serious/life-threatening infections, administer 12.5% of initial dose after each hemodialysis session (given in addition to the maintenance dose). Alternatively, may administer 500 mg every 12 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Give a full first dose, then give 25% of the dose at the usual interval</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVH: Loading dose of 2,000 mg followed by 1,000 to 2,000 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CVVHD/CVVHDF: Loading dose of 2,000 mg followed by either 1,000 mg every 8 hours or 2,000 mg every 12 hours (Heintz 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768966\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azactam in Dextrose: 1 g (50 mL); 2 g (50 mL) [sodium free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azactam: 1 g (1 ea); 2 g (1 ea) [sodium free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768893\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29837378\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: IV route is preferred for doses &gt;1,000 mg or in patients with severe life-threatening infections. Administer by IVP over 3 to 5 minutes or by intermittent infusion over 20 to 60 minute. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Doses &gt;1,000 mg should be administered IV. Do not mix with any local anesthetic agent. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768927\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Vials: Prior to reconstitution, store at room temperature; avoid excessive heat. After reconstitution, solutions for infusion in D5W, LR, NS, or other appropriate solution, with a final concentration of &le;20 mg/mL, should be used within 48 hours if stored at room temperature or within 7 days if refrigerated. Solutions for infusion with a final concentration of  &gt;20 mg/mL (if prepared with SWFI or NS <b>only</b>) should also be used within 48 hours if stored at room temperature or within 7 days if refrigerated; all other solutions for infusion with a final concentration &gt;20 mg/mL must be used immediately after preparation (unless prepared with SWFI or NS).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Premixed frozen containers: Store unused container frozen at &le;-20&deg;C (-4&deg;F). Frozen container can be thawed at room temperature of 25&deg;C (77&deg;F) or in a refrigerator, 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Thawed solution should be used within 48 hours if stored at room temperature or within 14 days if stored under refrigeration. <b>Do not freeze.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29837373\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Injection: Treatment of patients with documented multidrug resistant aerobic gram-negative infection in which beta-lactam therapy is contraindicated; used for UTI, lower respiratory tract infections, intra-abdominal infections, and gynecological infections caused by susceptible organisms (FDA approved in ages &ge;9 months and adults); treatment of susceptible skin and skin structure infections and septicemia (FDA approved in adults). Has also been used for the treatment of peritonitis in patients with peritoneal catheters.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768883\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aztreonam may be confused with azidothymidine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768916\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Phlebitis (intravenous), thrombophlebitis (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia (more common in children), neutropenia (more common in children), thrombocythemia (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum transaminases (children, more common with high dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Discomfort at injection site (intramuscular), erythema at injection site (intravenous: More common in children), pain at injection site (more common in children), swelling at injection site (intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal cramps, anaphylaxis, anemia, angioedema, breast tenderness, bronchospasm, chest pain, <i>Clostridium difficile</i> associated diarrhea, confusion, diaphoresis, diplopia, dizziness, dysgeusia, dyspnea, erythema multiforme, exfoliative dermatitis, flushing, gastrointestinal hemorrhage, hepatitis, hepatobiliary disease, hypotension, increased serum alkaline phosphatase, increased serum ALT (adults), increased serum AST (adults), induration at injection site, insomnia, jaundice, leukocytosis, malaise, myalgia, numbness of tongue, oral mucosa ulcer, pancytopenia, paresthesia, petechia, positive direct Coombs test, prolonged partial thromboplastin time, prolonged prothrombin time, pruritus, pseudomembranous colitis, purpura, seizure, thrombocytopenia, tinnitus, toxic epidermal necrolysis, urticaria, vaginitis, ventricular bigeminy (transient), ventricular premature contractions (transient), vertigo, vulvovaginal candidiasis, weakness, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to aztreonam or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768912\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Beta-lactam allergy: Rare cross-allergenicity to penicillins, cephalosporins, or carbapenems may occur; use with caution in patients with a history of hypersensitivity to beta-lactams.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use the injectable formulation with caution in patients with renal impairment; dosing adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Toxic epidermal necrolysis: Use with caution in bone marrow transplant patients with multiple risk factors for toxic epidermal necrolysis (TEN) (eg, sepsis, radiation therapy, drugs known to cause TEN); rare cases of TEN in this population have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768921\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768918\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104181&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768906\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768907\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Aztreonam crosses the placenta and can be detected in the fetus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29837379\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Periodic renal and hepatic function tests; monitor for stool frequency; monitor for signs of anaphylaxis during first dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768931\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Monobactam structure makes cross-allergenicity with beta-lactams unlikely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768933\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Well absorbed; IM and IV doses produce comparable serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Injection: Widely into body tissues, cerebrospinal fluid, bronchial secretions, peritoneal fluid, bile, and bone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Neonates: 0.26 to 0.36 L/kg; Children: 0.2 to 0.29 L/kg; Adults: 0.2 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion of antimicrobial agents from blood into CSF: Good only with inflammation (exceeds usual MICs)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Meninges: Inflamed: 8% to 40%; Normal: ~1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 56%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Injection: Hepatic (minor %)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: &lt;7 days, &le;2.5 kg: 5.5 to 9.9 hours; &lt;7 days, &gt;2.5 kg: 2.6 hours; 1 week to 1 month: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 months to 12 years: 1.7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with cystic fibrosis: 1.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal function: 1.7 to 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">End-stage renal disease (ESRD): 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM, IV push: Within 60 minutes; IV infusion: 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Injection: Urine (60% to 70% as unchanged drug); feces (~13% to 15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29768968\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Azactam in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (50 mL): $39.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (50 mL): $79.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Azactam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $34.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $69.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Aztreonam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $32.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $65.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040497\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Atreon (BD);</li>\n      <li>Azactam (AT, AU, BB, BE, BH, CH, CN, DK, EG, ES, FI, FR, GB, GR, JO, LB, LU, MT, NO, NZ, PK, PT, QA, SE, SG, TW, VE, ZA);</li>\n      <li>Azanem (BR);</li>\n      <li>Azenam (IN, LK);</li>\n      <li>Azeus (BR);</li>\n      <li>Aznam (RU);</li>\n      <li>Azom (IN);</li>\n      <li>Azonam (BD);</li>\n      <li>Aztram (PH);</li>\n      <li>Aztreo (IN);</li>\n      <li>Aztreobol (RU);</li>\n      <li>Bencipen (PE);</li>\n      <li>Finacide (PT);</li>\n      <li>Mezactam (KR);</li>\n      <li>Monobac (MX);</li>\n      <li>Primbactam (IT);</li>\n      <li>Reonam (BD);</li>\n      <li>SG-Nam (LK);</li>\n      <li>Treonam (PE);</li>\n      <li>Vebac (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azactam (aztreonam) injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosso JA and Black PG, &ldquo;The Use of Aztreonam in Pediatric Patients: A Review,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(1):20-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/1902290/pubmed\" target=\"_blank\" id=\"1902290\">1902290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Settler FR, Schramm M, and Swabb EA, &ldquo;Safety of Aztreonam and SQ 26,992 in Elderly Patients With Renal Insufficiency,&rdquo; <i>Rev Infect Dis</i>, 1985, (Suppl 4):5622.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/20034345 /pubmed\" target=\"_blank\" id=\"20034345 \">20034345 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stutman HR, Chartrand SA, Tolentino T, et al, &ldquo;Aztreonam Therapy for Serious Gram-Negative Infections in Children,&rdquo; <i>Am J Dis Child</i>, 1986, 140(11):1147-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/3766490/pubmed\" target=\"_blank\" id=\"3766490\">3766490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/22851742 /pubmed\" target=\"_blank\" id=\"22851742 \">22851742 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol. 2012;47(12):1147-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/22911974 /pubmed\" target=\"_blank\" id=\"22911974 \">22911974 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zobell JT, Young DC, Waters CD, et al, &quot;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: VI. Executive Summary,&quot; <i>Pediatr Pulmonol</i>, 2013, 48(6):525-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aztreonam-systemic-pediatric-drug-information/abstract-text/23359557/pubmed\" target=\"_blank\" id=\"23359557\">23359557</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104181 Version 33.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F29768890\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F29837372\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F30027754\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F29837376\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F29768966\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F29768893\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F29837378\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F29768927\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F29837373\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F29768883\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F29768916\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F29768911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F29768912\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F29768921\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F29768918\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F29768906\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F29768907\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F29837379\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F29768931\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F29768933\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F29768968\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45040497\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/104181|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aztreonam-systemic-drug-information\" class=\"drug drug_general\">Aztreonam (systemic): Drug information</a></li><li><a href=\"topic.htm?path=aztreonam-systemic-patient-drug-information\" class=\"drug drug_patient\">Aztreonam (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}